Find generic entry opportunities
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Sustained release comfort formulation for glaucoma therapy|
|Abstract:||Disclosed are nonstinging, sustained release ophthalmic formulations to control intraocular pressure in antiglaucoma therapy comprising a basic active, a cation exchange resin, and, inter alia, an acidic, mucomimetic polymer. Also disclosed are methods of treatment comprising administering such formulations topically to the eye when indicated for control and lowering of intraocular pressure.|
|Inventor(s):||Jani; Rajni (Fort Worth, TX), Harris; Robert G. (Fort Worth, TX)|
|Assignee:||Alcon Laboratories, Inc. (Fort Worth, TX)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Australia||1607495||<disabled in preview>|
|Australia||4575389||<disabled in preview>|
|Australia||621692||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.